2023
Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetite
2021
718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial
BECERRA L, MENDEZ B, KHAN F, MANTZOROS C, NOVAK P, LIOUTAS V, NGO L, NOVAK V, TREVINO J. 718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial. Diabetes 2021, 70 DOI: 10.2337/db21-718-p.Peer-Reviewed Original ResearchIntranasal insulinSerious adverse eventsCapillary glucoseSpouse/partnerContinuous glucose monitoringPlacebo groupAdverse eventsSubcutaneous insulinInsulin-dependent type 2 diabetesType 2 diabetes trialsLevel 1 hypoglycemiaPlacebo-treated participantsWeeks of treatmentFuture larger studiesType 2 diabetesLevel 2 hypoglycemiaNovo NordiskWorld Health OrganizationAdvisory PanelDiabetes (ACCORD) trialConcomitant administrationInsulin levelsKidney diseaseFunctional declineTerm safety